DPP3 (Dipeptidyl Peptidase 3)
A zinc-dependent metallopeptidase involved in pain modulation, blood pressure regulation, and cancer biology.
Gene Information Card
| Symbol | DPP3 |
|---|---|
| Full Name | Dipeptidyl peptidase 3 |
| Gene Type | Protein coding |
| Chromosomal Location | 11q12.2 |
| NCBI Gene ID | 10072 ncbi.nlm.nih.gov/gene/10072 |
| Ensembl ID | ENSG00000149257 |
| UniProt ID | Q9NY33 |
| OMIM ID | 126800 |
| HGNC ID | 3009 |
| Aliases | DPP III, DPP3_HUMAN, MGC26243 |
Description
DPP3 encodes dipeptidyl peptidase 3, a zinc-dependent metallopeptidase that cleaves dipeptides from the N-terminus of substrates. It is involved in the degradation of bioactive peptides such as angiotensin III and enkephalins, thereby playing roles in blood pressure regulation and pain modulation. The enzyme is also implicated in oxidative stress response and cancer progression.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Hypertension | DPP3 degrades angiotensin III, a vasoconstrictor; altered activity may affect blood pressure regulation. | OMIM #126800; NCBI Gene |
| Pain disorders | DPP3 cleaves enkephalins, endogenous opioid peptides; modulation of DPP3 activity influences pain perception. | UniProt Q9NY33; PubMed studies |
| Cancer (various) | DPP3 overexpression or mutation linked to tumor growth, metastasis, and poor prognosis in breast, lung, and colorectal cancers. | COSMIC; ClinVar; PubMed |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Kidney | 8.3 | Medium |
| Liver | 6.1 | Low |
| Heart | 5.4 | Low |
| Lung | 4.8 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK293 | 15.2 | High expression |
| HeLa | 10.1 | Moderate expression |
| A549 | 7.3 | Low expression |
| MCF7 | 6.5 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1?) | Missense | <0.01% | Likely loss of function; start codon loss |
| c.487C>T (p.Arg163Trp) | Missense | 0.02% | Reduced enzymatic activity |
| c.1024G>A (p.Glu342Lys) | Missense | 0.01% | Altered substrate specificity |
Mutation functional classification
Loss of Function (LOF)
Mutations such as p.Met1? and p.Arg163Trp reduce or abolish DPP3 catalytic activity, impairing peptide degradation.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported in DPP3.
Dominant Negative (DN)
No evidence of dominant-negative effects for DPP3 mutations.
View complete mutation data：
Gene Ontology (GO)
| • aminopeptidase activity (GO:0004177) | • metallopeptidase activity (GO:0008237) |
| • proteolysis (GO:0006508) | • cytoplasm (GO:0005737) |
| • cytosol (GO:0005829) |
Pathways
• Angiotensin III degradation pathway
• Enkephalin degradation pathway
• Oxidative stress response
Protein Summary
DPP3 is a 737-amino-acid zinc-dependent metallopeptidase that removes N-terminal dipeptides from substrates including angiotensin III and enkephalins. It is ubiquitously expressed with highest levels in brain and kidney. The enzyme exists as a monomer and is involved in blood pressure regulation, pain modulation, and cellular redox balance. Altered expression or mutations are associated with hypertension, pain disorders, and several cancers.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| DPP3 Knockout HEK293 Cell Line | EDJ-KQ6888 | Human | 10072 | Details Get a Quote |
| DPP3 Knockout A-549 Cell Line | EDJ-KQ30117 | Human | 10072 | Details Get a Quote |
| DPP3 Knockout HCT 116 Cell Line | EDJ-KQ31492 | Human | 10072 | Details Get a Quote |
| DPP3 Knockout HeLa Cell Line | EDJ-KQ31493 | Human | 10072 | Details Get a Quote |
